Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kybella for Cutaneous Neurofibromas in NF1
NCT06300502Phase 1Enrolling by invitation
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Neobella in cutaneous neurofibroma (cNF) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Apr 2025; status: enrolling by invitation.
02
Drugs
Neobella
03
Conditions
cutaneous neurofibroma (cNF)
Beyond the preview
Go deeper on NCT06300502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06300502.